BioPharmX Corp fka BPMX

[Whos_Who]

I think we all know that as we look at fund raising, we need capital to move forward with the Phase 3 trial and as we look at the landscape of way to do that but non-dilutive and dilutive as you describe, right, there are several scenarios that are ahead of us and I think I talked about this in generally before where clearly partnering and licensing and other things of that, that [ph] would be a non-dilutive event and those are things that accompany with the new technology and innovative drug platform that we have, clearly always wants to explore and look at. And in parallel to that, as we've done previously leading upto now, we always also look at the capital markets as another alternative for raising funds. So I think we're very conscious and thoughtful about that approach, we are looking at all aspects that make the most sense for the shareholders and for the return for all the investors of the business and we'll continue to do that.
Anja Krammer